Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 22, 2023
Reporting Period: Event date of September 19, 2023
Business Overview: The Company is an emerging growth company incorporated in British Columbia, Canada, with common shares traded on The Nasdaq Capital Market under the symbol "INM".
Key Financial Metrics
This filing is a current report regarding a listing status event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material event reported is a deficiency in compliance with Nasdaq listing standards:
- Event: On September 19, 2023, the Company received written notice from Nasdaq regarding a failure to meet the minimum bid price requirement.
- Deficiency: The average closing bid price of the Company's common shares was below $1.00 per share for 30 consecutive trading days, violating Nasdaq Listing Rule 5550(a)(2).
- Immediate Impact: The notice has no immediate impact on the listing; shares continue to trade on Nasdaq under the symbol "INM".
Outlook, Risks, and Management Commentary
Management Action Plan: The Company has been granted a 180-calendar-day grace period to cure the deficiency and regain compliance. Management intends to monitor the closing share price and explore available options to restore compliance.
Risks and Contingencies:
- Delisting Risk: If the Company fails to evidence compliance within the 180-day period, Nasdaq is expected to notify the Company that its shares are subject to delisting.
- Appeal Process: In the event of a delisting determination, the Company may appeal to a Nasdaq Hearings Panel. Securities would likely continue to trade pending the appeal outcome.
- Uncertainty: There is no assurance that an appeal would be successful or that the Company will be able to meet the terms of any extension granted by the Panel.
Key Facts for Investor Verification
- Verify the current trading price of "INM" to assess the likelihood of regaining the $1.00 minimum bid price within the 180-day window.
- Monitor future filings for any announcements regarding reverse stock splits or other corporate actions intended to cure the deficiency.
- Confirm the status of the 180-day compliance period and any potential appeals filed with the Nasdaq Hearings Panel.
- Review the Company's most recent 10-K or 10-Q filings for financial health data, as this 8-K contains no financial metrics.